Suppr超能文献

供者和受者 SARS-CoV-2 疫苗接种或感染对造血细胞移植后免疫的影响。

Impact of Donor and Recipient SARS-CoV-2 Vaccination or Infection on Immunity after Hematopoietic Cell Transplantation.

机构信息

Division of Infectious Diseases, Brigham and Women's Hospital, Boston, Massachusetts; Dana-Farber Cancer Institute, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

Harvard Medical School, Boston, Massachusetts; Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, Massachusetts; School of Pharmacy, National Taiwan University, Taipei, Taiwan.

出版信息

Transplant Cell Ther. 2023 May;29(5):337.e1-337.e5. doi: 10.1016/j.jtct.2023.01.025. Epub 2023 Feb 2.

Abstract

The role of donor and recipient Coronavirus disease 2019 (COVID-19) immunologic status pre-transplantation has not been fully investigated in allogeneic hematopoietic stem cell transplantation (HSCT) recipients. Given the poor immunogenicity to vaccines in this population and the serious outcomes of COVID-19, adoptive transfer of immunity may offer important insight into improving protection for this vulnerable population. In this study, we evaluated the role of adoptive transfer of immunity at 1 month post-transplantation and 6 months post-transplantation after vaccination of recipients, based on pre-transplantation severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and infection exposures of both recipient and donor. Using banked specimens from related donor allogeneic HSCT recipients and clinical data from both donors and recipients, anti-Spike (S) IgG titers were analyzed at 1, 3, and 6 months post-transplantation according to prior SARS-CoV-2 immunologic exposures. Recipients were excluded if they had received SARS-CoV-2 monoclonal antibodies or had infection in the first 6 months post-transplantation. Of the 53 recipient-donor pairs, 29 donors and 24 recipients had prior SARS-CoV-2 immunologic exposure. Recipient-donor pairs with no prior SARS-CoV-2 exposure (D0R0) had significantly lower anti-S IgG titers at 1 month compared to those with prior exposures (D1R1) (D0R0: median, 2.43 [interquartile range (IQR), .41 to 3.77]; D1R1: median, 8.42; IQR, 5.58 to 12.20]; P = .008). At 6 months, anti-S IgG titers were higher in recipients who were vaccinated at 3 months post-transplantation in the D1R1 cohort (median IgG, 148.34; IQR, 92.36 to 204.33) compared with the D0R0 cohort (median IgG, 38.74; IQR, 8.93 to 119.71). Current strategies should be optimized to enhance SARS-CoV-2 protection for HSCT recipients, including augmentation of the immune response for both donors and recipients prior to transplantation.

摘要

移植前供体和受者 2019 年冠状病毒病(COVID-19)免疫状态的作用在异基因造血干细胞移植(HSCT)受者中尚未得到充分研究。鉴于该人群对疫苗的免疫原性较差,以及 COVID-19 的严重后果,免疫的适应性转移可能为改善这一脆弱人群的保护提供重要的见解。在这项研究中,我们根据移植前受者和供者 SARS-CoV-2 疫苗接种和感染暴露情况,评估了移植后 1 个月和 6 个月时受者接种疫苗后免疫适应性转移的作用。使用来自相关供体异基因 HSCT 受者的银行标本和供者和受者的临床数据,根据 SARS-CoV-2 免疫暴露情况,在移植后 1、3 和 6 个月分析抗刺突(S)IgG 滴度。如果受者在移植后 6 个月内接受了 SARS-CoV-2 单克隆抗体或感染,则排除在外。在 53 对供受者中,29 名供者和 24 名受者有 SARS-CoV-2 免疫暴露史。无 SARS-CoV-2 暴露史的供受者(D0R0)在 1 个月时的抗 S IgG 滴度明显低于有暴露史的供受者(D1R1)(D0R0:中位数,2.43[四分位距(IQR),0.41 至 3.77];D1R1:中位数,8.42;IQR,5.58 至 12.20];P=0.008)。在 6 个月时,D1R1 队列中在移植后 3 个月接种疫苗的受者抗 S IgG 滴度较高(中位数 IgG,148.34;IQR,92.36 至 204.33),而 D0R0 队列中抗 S IgG 滴度较低(中位数 IgG,38.74;IQR,8.93 至 119.71)。目前的策略应加以优化,以增强 HSCT 受者对 SARS-CoV-2 的保护,包括在移植前增强供者和受者的免疫反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8791/9891788/8c6cbb8c3385/gr1_lrg.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验